A5040223652- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Genomics and Rare Diseases
- CNS Lymphoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- Ethics in Clinical Research
- Biomedical and Engineering Education
- Cardiac tumors and thrombi
- Cancer Research and Treatments
- Molecular Biology Techniques and Applications
Memorial Sloan Kettering Cancer Center
2015-2024
Kettering University
2022
New York Hospital Queens
2017
Presbyterian Hospital
2017
NewYork–Presbyterian Hospital
2017
Cornell University
2015-2017
Weill Cornell Medicine
2017
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Abstract The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation cWGTS challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting prioritization findings. In a prospective research study we develop workflow that reports comprehensive 9 days. Comparison diagnostic panel assays demonstrates potential capture all reported mutations with comparable...
Abstract Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic relapse site. Subclonal...
Abstract Limited clinical data are available regarding the utility of multikinase inhibition in neuroblastoma. Repotrectinib (TPX-0005) is a inhibitor that targets ALK, TRK, JAK2/STAT, and Src/FAK, which have all been implicated pathogenesis We evaluated preclinical activity repotrectinib monotherapy combination with chemotherapy as potential therapeutic approach for relapsed/refractory In vitro sensitivity to repotrectinib, ensartinib, cytotoxic was neuroblastoma cell lines. vivo antitumor...
To evaluate outcomes and prognostic markers among children with relapsed Hodgkin lymphoma (HL) treated autologous stem cell transplant (ASCT), we conducted a retrospective analysis of 36 consecutive pediatric patients at Memorial Sloan Kettering Cancer Center from 1989 to 2013. With median follow-up 9.6 years, the 10-year overall survival (OS) event-free (EFS) were 74.1 67.1% respectively. Absence B-symptoms, chemotherapy-sensitive disease, date after 1997 each associated superior EFS [HR...
PURPOSE The tyrosine kinase receptor anaplastic lymphoma (ALK) can be abnormally activated in neuroblastoma, and somatic ALK mutations occur 6%-10% of patients. differential clinical impact these has not been clearly elucidated. METHODS Data on patients with neuroblastoma harboring were retrospectively analyzed. sequencing was performed by whole-genome sequencing, hybrid-based capture targeted exomes, or hotspot mutation profiling. site characteristics, response to treatment, survival In a...
11503 Background: Prexasertib (PRX) is an inhibitor of CHK1, prevents DNA repair leading to mitotic catastrophe, and can enhance the activity DNA-damaging chemotherapy. Translocation driven sarcomas exhibit high levels replication stress have demonstrated susceptibility CHK1 inhibition in preclinical models. Desmoplastic small round cell tumor (DSRCT) rhabdomyosarcoma (RMS) are aggressive children, adolescents young adults for which novel therapies urgently required. Methods: We conducted a...
ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.
Abstract BACKGROUND Genomic profiling and precision medicine have revolutionized cancer care but are not accessible to all due high costs, insurance issues, limited access testing facilities or qualified personnel. We established a program providing free clinical genomic worldwide (Make-An-IMPACT) report findings from the pediatric CNS tumor cohort. METHODS Following referral from: (1) physician, (2) disease-specific advocacy group, (3) submission of contact information through website,...
Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity how it may drive treatment resistance. We performed whole-genome sequencing of 37 samples from eight patients with relapsed or refractory osteosarcoma. Each patient had at least one sample a primary site metastatic relapse site. identified subclonal copy number alterations all but patient. observed that five patients,...
Introduction: Treatment with dose-adjusted EPOCH chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in multi-center setting. We report a large, retrospective analysis children adults PMBCL treated DA-EPOCH-R to characterize outcomes, specifically assess both pediatric adult patients, evaluate potential prognostic factors. Methods: 156 patients across 24 academic medical centers were...
3063 Background: Next generation sequencing (NGS) assays have accelerated the identification of mutations and potential matched targeted therapies for patients with cancer. However, a significant proportion do not derive clinical benefit from panel approaches. Cancer whole genome transcriptome (cWGTS) offers opportunity to fully characterize tumors, but are challenged by cost computational resource requirements, concerns assay sensitivity, need deliver curated results within clinically...
<p>Supplementary figures and tables</p>
<p>Supplementary figures and tables</p>
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...
<p>Supplementary Figures</p>
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...
<p>Supplementary Figures</p>
<div>Abstract<p>Limited clinical data are available regarding the utility of multikinase inhibition in neuroblastoma. Repotrectinib (TPX-0005) is a inhibitor that targets ALK, TRK, JAK2/STAT, and Src/FAK, which have all been implicated pathogenesis We evaluated preclinical activity repotrectinib monotherapy combination with chemotherapy as potential therapeutic approach for relapsed/refractory <i>In vitro</i> sensitivity to repotrectinib, ensartinib, cytotoxic was...
<div>Abstract<p>Limited clinical data are available regarding the utility of multikinase inhibition in neuroblastoma. Repotrectinib (TPX-0005) is a inhibitor that targets ALK, TRK, JAK2/STAT, and Src/FAK, which have all been implicated pathogenesis We evaluated preclinical activity repotrectinib monotherapy combination with chemotherapy as potential therapeutic approach for relapsed/refractory <i>In vitro</i> sensitivity to repotrectinib, ensartinib, cytotoxic was...
Abstract Background: Recapitulation of the full spectrum genomic changes driving patient tumors have resulted in increased use patient-derived xenograft (PDX) models studies basic cancer biology and preclinical drug development. Given translational potential PDXs limited availability pediatric models, we established a PDX program to expand existing collection community enable pre- post-clinical studies. Methods: generation requests were integrated into clinical workflows maximize...